HBOT for Diabetic Foot Ulcers: What the Cochrane Review Actually Found
A Cochrane review found a short-term healing signal for diabetic foot ulcers but no lasting benefit and no reduction in amputations. Here is the honest reading of the evidence.
Why chronic wounds are studied at all
Diabetic foot ulcers are one of the few chronic conditions where hyperbaric oxygen therapy has a place on recognized indication lists and can qualify for reimbursement. The rationale is that raising tissue oxygen levels may support healing in wounds where poor circulation limits recovery. But being a recognized indication is not the same as being a cure, and the most-cited evidence base is more measured than the marketing around it.
The reference point here is the Cochrane systematic review on hyperbaric oxygen therapy for chronic wounds, last updated in 2015, which pooled the available randomized trials.
The short-term healing signal
For diabetic foot ulcers, the reviewers pooled five trials with 205 participants and found an increase in the rate of ulcer healing at six weeks, reported as a risk ratio of 2.35 with a 95 percent confidence interval from 1.19 to 4.62. In plain terms, ulcers in the HBOT groups were more likely to have healed at the six-week mark than those receiving standard care alone.
It is worth noting that the review looked at chronic wounds more broadly, including venous, arterial, and pressure ulcers, not only diabetic ones. For those other wound types the reviewers found too little evidence to draw conclusions, which is why the diabetic foot ulcer is the setting most often cited. The therapy in these trials was always an addition to standard wound care, not a stand-alone treatment.
That is a real signal, but it is a short-term one, and the trials feeding into it were small.
What did not hold up
The same review found that the six-week benefit was not sustained at longer follow-up, with no clear difference in healing by around one year. Just as importantly, the 2015 update concluded that HBOT did not reduce the rate of major amputation. This is a notable point, because earlier versions of the review had suggested a possible reduction in amputations, and that more optimistic finding did not survive the updated analysis.
The reviewers were also candid about quality. They noted that the trials had various flaws in design or reporting, which left them not confident in the results, and they called for better research.
Reading this as a buyer
The honest summary is that HBOT, delivered alongside proper wound care, shows a short-term healing benefit for diabetic foot ulcers, but the evidence does not show a lasting advantage or fewer amputations, and the underlying trials are limited. That is a meaningful but modest picture, and it sits at odds with pages that present wound healing as a guaranteed outcome.
Anyone weighing equipment for this reason should note that recognized wound protocols are hospital-grade treatments at prescribed pressures, which is a different world from general wellness marketing. If you are researching the market, a neutral primer at buying guide can help separate device categories from clinical claims before any money changes hands.
A diabetic foot ulcer is a serious condition that can worsen quickly. Decisions about whether HBOT belongs in a treatment plan should be made by a physician and wound-care team managing the ulcer, not on the strength of a single statistic.